[Stomach diseases].
A new generation of PPI are presently in clinical trials. They are characterized by a quicker and longer effectiveness, very useful for reflux disease treatment. We have to note that the enthusiasm towards the endoscopy treatment for reflux disease is clearly deceasing and two types of procedures have even been recalled from the market. In Helicobacter pylori eradication treatments the tendency tends towards high doses of antibiotics for the second option treatments. The indication for a COX-2 treatment is largely reduced due to the cardiac side effects of certain COX-2. For the patients with high risk of gastro-duodenal toxicity through AINS, the alternative remains the classical non-specific AINS treatment associated with a PPI.
Service de Gastro-entérologie et d'Hépatologie, CHUV, 1011 Lausanne.
C
C
Nichita
F
F
Viani
F
F
Vouillamoz
P
P
Jornod
V
V
Kessler-Brondolo
G
G
Dorta
D002986:Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004935:Esophageal Diseases / Q000503:physiopathology / Q000628:therapy*; D016481:Helicobacter Infections / Q000188:drug therapy; D006801:Humans; D054328:Proton Pump Inhibitors; D012307:Risk Factors; D013272:Stomach Diseases / Q000503:physiopathology / Q000628:therapy*; D013276:Stomach Ulcer / Q000188:drug therapy*
D052246:Cyclooxygenase 2 Inhibitors; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors